4 February 2021 - Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in adult patients with and without type 2 diabetes.
AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction.